
Pre-emptive transjugular intrahepatic portosystemic shunt in pediatric cystic fibrosis-related liver disease and portal hypertension : prospective long-term results
- Author
- Laurens Hermie (UGent) , Stephanie Van Biervliet (UGent) , Anne Hoorens (UGent) , Lien Van Cauwenberghe (UGent) , Eddy Robberecht (UGent) and Luc Defreyne (UGent)
- Organization
- Abstract
- PURPOSE Portal hypertension (PHT) and its sequelae are the most clinically important manifestations in cystic fibrosis -related liver disease (CFLD). This paper aimed to evaluate the safety and efficacy of a pre-emptive transjugular intrahepatic portosystemic shunt (TIPS) to prevent PHT-related complications in pediatric patients with CFLD. METHODS This was a prospective single -arm study on pediatric patients with CFLD, signs of PHT, and preserved liver function who underwent a pre-emptive TIPS in a single tertiary CF center between 2007 and 2012. The long-term safety and clinical efficacy were assessed. RESULTS A pre-emptive TIPS was performed on seven patients with a mean age of 9.2 years (+/- standard deviation: 2.2). The procedure was technically successful in all patients, with an estimated median primary patency of 10.7 years [interquar tile range (IQR) 0.5-10.7)]. No variceal bleeding was observed during the median follow-up of 9 years (IQR 8.1-12.9). In two patients with advanced PHT and rapidly progressive liver disease, severe thrombocytopenia could not be stopped. Subsequent liver transplantation revealed biliary cirrhosis in both patients. In the remaining patients with early PHT and milder porto-sinusoidal vascular disease, symptomatic hypersplenism did not occur, and liver function remained stable until the end of the follow-up. Inclusion for pre-emptive TIPS was discontinued in 2013 following an episode of severe hepatic encephalopathy. CONCLUSION TIPS is a feasible treatment with encouraging long-term primary patency to avoid variceal bleeding in selected patients with CF and PHT. However, as the progression of liver fibrosis, thrombocytopenia, and splenomegaly is inevitable, the clinical benefits due to pre-emptive placement appear to be minor.
- Keywords
- Cardiology and Cardiovascular Medicine, Radiology, Nuclear Medicine and imaging, hypersplenism, variceal bleeding, primary prophylaxis, shunt, transjugular intrahepatic portosystemic, children, portal hypertension, liver diseases, Cystic fibrosis
Downloads
-
DIR-30-55.pdf
- full text (Published version)
- |
- open access
- |
- |
- 3.88 MB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-01HMY4T27A3Y67ZVEX6GAKGJSH
- MLA
- Hermie, Laurens, et al. “Pre-Emptive Transjugular Intrahepatic Portosystemic Shunt in Pediatric Cystic Fibrosis-Related Liver Disease and Portal Hypertension : Prospective Long-Term Results.” DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY, vol. 30, no. 1, 2024, pp. 55–64, doi:10.4274/dir.2022.221818.
- APA
- Hermie, L., Van Biervliet, S., Hoorens, A., Van Cauwenberghe, L., Robberecht, E., & Defreyne, L. (2024). Pre-emptive transjugular intrahepatic portosystemic shunt in pediatric cystic fibrosis-related liver disease and portal hypertension : prospective long-term results. DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY, 30(1), 55–64. https://doi.org/10.4274/dir.2022.221818
- Chicago author-date
- Hermie, Laurens, Stephanie Van Biervliet, Anne Hoorens, Lien Van Cauwenberghe, Eddy Robberecht, and Luc Defreyne. 2024. “Pre-Emptive Transjugular Intrahepatic Portosystemic Shunt in Pediatric Cystic Fibrosis-Related Liver Disease and Portal Hypertension : Prospective Long-Term Results.” DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY 30 (1): 55–64. https://doi.org/10.4274/dir.2022.221818.
- Chicago author-date (all authors)
- Hermie, Laurens, Stephanie Van Biervliet, Anne Hoorens, Lien Van Cauwenberghe, Eddy Robberecht, and Luc Defreyne. 2024. “Pre-Emptive Transjugular Intrahepatic Portosystemic Shunt in Pediatric Cystic Fibrosis-Related Liver Disease and Portal Hypertension : Prospective Long-Term Results.” DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY 30 (1): 55–64. doi:10.4274/dir.2022.221818.
- Vancouver
- 1.Hermie L, Van Biervliet S, Hoorens A, Van Cauwenberghe L, Robberecht E, Defreyne L. Pre-emptive transjugular intrahepatic portosystemic shunt in pediatric cystic fibrosis-related liver disease and portal hypertension : prospective long-term results. DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY. 2024;30(1):55–64.
- IEEE
- [1]L. Hermie, S. Van Biervliet, A. Hoorens, L. Van Cauwenberghe, E. Robberecht, and L. Defreyne, “Pre-emptive transjugular intrahepatic portosystemic shunt in pediatric cystic fibrosis-related liver disease and portal hypertension : prospective long-term results,” DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY, vol. 30, no. 1, pp. 55–64, 2024.
@article{01HMY4T27A3Y67ZVEX6GAKGJSH, abstract = {{PURPOSE Portal hypertension (PHT) and its sequelae are the most clinically important manifestations in cystic fibrosis -related liver disease (CFLD). This paper aimed to evaluate the safety and efficacy of a pre-emptive transjugular intrahepatic portosystemic shunt (TIPS) to prevent PHT-related complications in pediatric patients with CFLD. METHODS This was a prospective single -arm study on pediatric patients with CFLD, signs of PHT, and preserved liver function who underwent a pre-emptive TIPS in a single tertiary CF center between 2007 and 2012. The long-term safety and clinical efficacy were assessed. RESULTS A pre-emptive TIPS was performed on seven patients with a mean age of 9.2 years (+/- standard deviation: 2.2). The procedure was technically successful in all patients, with an estimated median primary patency of 10.7 years [interquar tile range (IQR) 0.5-10.7)]. No variceal bleeding was observed during the median follow-up of 9 years (IQR 8.1-12.9). In two patients with advanced PHT and rapidly progressive liver disease, severe thrombocytopenia could not be stopped. Subsequent liver transplantation revealed biliary cirrhosis in both patients. In the remaining patients with early PHT and milder porto-sinusoidal vascular disease, symptomatic hypersplenism did not occur, and liver function remained stable until the end of the follow-up. Inclusion for pre-emptive TIPS was discontinued in 2013 following an episode of severe hepatic encephalopathy. CONCLUSION TIPS is a feasible treatment with encouraging long-term primary patency to avoid variceal bleeding in selected patients with CF and PHT. However, as the progression of liver fibrosis, thrombocytopenia, and splenomegaly is inevitable, the clinical benefits due to pre-emptive placement appear to be minor.}}, author = {{Hermie, Laurens and Van Biervliet, Stephanie and Hoorens, Anne and Van Cauwenberghe, Lien and Robberecht, Eddy and Defreyne, Luc}}, issn = {{1305-3825}}, journal = {{DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY}}, keywords = {{Cardiology and Cardiovascular Medicine,Radiology, Nuclear Medicine and imaging,hypersplenism,variceal bleeding,primary prophylaxis,shunt,transjugular intrahepatic portosystemic,children,portal hypertension,liver diseases,Cystic fibrosis}}, language = {{eng}}, number = {{1}}, pages = {{55--64}}, title = {{Pre-emptive transjugular intrahepatic portosystemic shunt in pediatric cystic fibrosis-related liver disease and portal hypertension : prospective long-term results}}, url = {{http://doi.org/10.4274/dir.2022.221818}}, volume = {{30}}, year = {{2024}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: